{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:25:06Z","timestamp":1784035506681,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AbbVie GK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Measurable residual disease (MRD), defined as the persistence of minimal levels of leukemic cells following therapeutic intervention, serves as a pivotal prognostic biomarker in patients with chronic lymphocytic leukemia (CLL). We conducted a multicenter, cross-sectional study to assess MRD in Japanese patients with relapsed or refractory CLL. All patients received venetoclax-based therapy for 24\u00a0months. MRD in peripheral blood (PB) and bone marrow was assessed by multicolor flow cytometry using surface markers, including kappa and lambda light chains of surface immunoglobulins. The primary and secondary outcomes were the proportions of patients who achieved undetectable MRD (uMRD,\u2009&lt;\u200910\n                    <jats:sup>\u22124<\/jats:sup>\n                    CLL cells) and low-MRD (&lt;\u200910\n                    <jats:sup>\u22122<\/jats:sup>\n                    and\u2009\u2265\u200910\n                    <jats:sup>\u22124<\/jats:sup>\n                    CLL cells) after 24\u00a0months of venetoclax treatment. From June 2023 to December 2024, 60 patients were enrolled, and 51 were analyzed. The median age was 78\u00a0years, and 68.6% were male. Thirty-four of 51 patients (66.7%) achieved uMRD, and 8 (15.7%) achieved low-MRD in PB after at least 24\u00a0months of venetoclax treatment. Assessment of MRD in PB by flow cytometry is helpful for evaluating treatment response, informing clinical decision-making, and predicting long-term outcomes in clinical practice. Further analyses are warranted to investigate the use of MRD in treatment decision-making and prognostication.Kindly check the inserted city in affiliations 5 and 9.The city names were corrrected.\n                  <\/jats:p>","DOI":"10.1007\/s12185-025-04149-z","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T13:17:40Z","timestamp":1766927860000},"page":"678-685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-3227","authenticated-orcid":false,"given":"Hirotaka","family":"Matsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhaeng","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"key":"4149_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1470-2045(00)00418-6","volume":"2","author":"T Szczepa\u0144ski","year":"2001","unstructured":"Szczepa\u0144ski T, Orf\u00e3o A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2:409\u201317.","journal-title":"Lancet Oncol"},{"key":"4149_CR2","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","volume":"35","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021;35:3059\u201372.","journal-title":"Leukemia"},{"key":"4149_CR3","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"4149_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37:269\u201377.","journal-title":"J Clin Oncol"},{"key":"4149_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"M Hallek","year":"2025","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. 2025;100:450\u201380.","journal-title":"Am J Hematol"},{"key":"4149_CR6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","volume":"131","author":"N Dimier","year":"2018","unstructured":"Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018;131:955\u201362.","journal-title":"Blood"},{"key":"4149_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood-2015-08-634816","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016;127:279\u201386.","journal-title":"Blood"},{"key":"4149_CR8","unstructured":"The Japanese Society of Hematology, Practical Guidelines for Hematological Malignancies. 2024 revised http:\/\/www.jshem.or.jp\/gui-hemali\/1_5.html#soron. Accessed 14 Oct 2025."},{"key":"4149_CR9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"B Eichhorst","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, Kater AP, Gregoret M, Hallek M, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:762\u20138.","journal-title":"Ann Oncol"},{"key":"4149_CR10","unstructured":"NCCN Guidelines. Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Version: 1.2026 https:\/\/www.nccn.org\/guidelines\/nccn-guidelines. Accessed 14 Oct 2025."},{"key":"4149_CR11","unstructured":"Food and Drug Administration. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment; Guidance for Industry; Availability. Docket ID: FDA-2018-D-3090. https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3090. Accessed 14 Oct 2025."},{"key":"4149_CR12","unstructured":"European Medicines Agency. Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/evaluation-anticancer-medicinal-products-man-appendix-4-condition-specific-guidance-revision-2_en.pdf. Accessed 14 Oct 2025"},{"key":"4149_CR13","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1182\/blood.2024025525","volume":"145","author":"AP Kater","year":"2025","unstructured":"Kater AP, Harrup R, Kipps T, Eichhorst B, Owen CJ, Assouline S, et al. The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL. Blood. 2025;145:2733\u201345.","journal-title":"Blood"},{"key":"4149_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s12185-023-03646-3","volume":"118","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, et al. Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax. Int J Hematol. 2023;118:526\u20138.","journal-title":"Int J Hematol"},{"key":"4149_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cyto.b.21595","volume":"94","author":"AC Rawstron","year":"2018","unstructured":"Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom. 2018;94:121\u20138.","journal-title":"Cytometry B Clin Cytom"},{"key":"4149_CR16","doi-asserted-by":"publisher","first-page":"13452","DOI":"10.1038\/s41598-024-64398-6","volume":"14","author":"Y Aruga","year":"2024","unstructured":"Aruga Y, Ikeda C, Matsushita H, Makita S, Fukuhara S, Munakata W, et al. The kappa\/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype. Sci Rep. 2024;14:13452.","journal-title":"Sci Rep"},{"key":"4149_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","volume":"140","author":"JF Seymour","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF, D\u2019Rozario J, Owen CJ, Assouline S, et al. Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140:839\u201350.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4149_CR18","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1182\/blood-2021-147685","volume":"138","author":"P Baltasar","year":"2021","unstructured":"Baltasar P, Jos\u00e9 Terol M, Marquet Palomanes J, Ram\u00edrez Payer A, Moreno C, Osorio S, et al. Efficacy and safety of treatment venetoclax monotherapy or combined with rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) in the real-world setting in Spain: the Venares study. Blood. 2021;138(Supplement 1):1561.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4149_CR19","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1182\/blood-2023-188129","volume":"142","author":"BM Heyman","year":"2023","unstructured":"Heyman BM, Choi MY, Kipps TJ. Comparison of venetoclax based treatments for patients with relapsed\/refractory chronic lymphocytic leukemia. Blood. 2023;142(Supplement 1):1907.","journal-title":"Blood"},{"key":"4149_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"N Engl J Med"},{"key":"4149_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12185-020-03024-3","volume":"113","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, et al. Phase 1\/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol. 2021;113:370\u201380.","journal-title":"Int J Hematol"},{"key":"4149_CR22","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D\u2019Rozario J, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38:4042\u201354.","journal-title":"J Clin Oncol"},{"key":"4149_CR23","doi-asserted-by":"publisher","first-page":"106704","DOI":"10.1016\/j.leukres.2021.106704","volume":"111","author":"H El Siba","year":"2021","unstructured":"El Siba H, Wei W, Sa AW, Hong F, Sofia G, Mehrnoosh T, et al. Hematogones with light chain restriction: a potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens. Leuk Res. 2021;111:106704.","journal-title":"Leuk Res"},{"key":"4149_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cyto.b.21837","volume":"98","author":"YJ Xiu","year":"2020","unstructured":"Xiu YJ, Joanne L, Afshin S, et al. Artifactual kappa light chain restriction of marrow hematogones: a potential diagnostic pitfall in minimal residual disease assessment of plasma cell myeloma patients on daratumumab. Cytometry B Clin Cytom. 2020;98:68\u201374.","journal-title":"Cytometry B Clin Cytom"},{"key":"4149_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3960\/jslrt.20014","volume":"60","author":"T Uchiyama","year":"2020","unstructured":"Uchiyama T, Yokoyama A, Aoki S. Measurable residual disease in the treatment of chronic lymphocytic leukemia. J Clin Exp Hematop. 2020;60:138\u201345.","journal-title":"J Clin Exp Hematop"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04149-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:32:33Z","timestamp":1778736753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04149-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4149"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04149-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H Matsui has received lecture fees from AbbVie G.K. and serves as a member of the journal\u2019s editorial board, J Takizawa has received research funding from Mitsubishi Tanabe Pharma Corporation, and lecture fees from Janssen Pharmaceutical K.K., K Kojima has received lecture fees from Janssen Pharmaceutical K.K., AstraZeneca K.K., AbbVie G.K., BeOne Medicines, C Ikeda has received lecture fees from AbbVie G.K., Y Aruga has received lecture fees from AbbVie G.K., H Matsushita has received research funding from Nippon Becton Dickinson Co. Ltd., Sysmex Corporation, lecture fees from AbbVie G.K and donation from Tosoh Corporation., R Suzuki has received research funding from Meiji Seika Pharma Co. Ltd., and lecture fees from Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Meiji Seika Pharma Co. Ltd., AbbVie GK, AstraZeneca K.K., H Sakamoto are employees of Sapporo Clinical Laboratory Inc., R Takenaka, J Park, and T Morita are employees of AbbVie G.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}